A Case of Biopharmaceutical-Induced Catatonia and the Implication of a Novel Mechanism

Catatonia can be described structurally as a motor dysregulation syndrome with a concomitant behavioral component. However, despite its initial recognition nearly 150 years ago, the exact pathophysiological causes underlying this syndrome are still somewhat unknown and are potentially variable. This...

Full description

Saved in:
Bibliographic Details
Published inThe journal of ECT Vol. 36; no. 3; p. e29
Main Authors Durns, Tyler, Rich, Bianca, Benson, Carlie, Mickey, Brian, Weischedel, Kamile
Format Journal Article
LanguageEnglish
Published United States 01.09.2020
Online AccessGet more information

Cover

More Information
Summary:Catatonia can be described structurally as a motor dysregulation syndrome with a concomitant behavioral component. However, despite its initial recognition nearly 150 years ago, the exact pathophysiological causes underlying this syndrome are still somewhat unknown and are potentially variable. This report reviews a case of a patient with multiple catatonic episodes precipitated by the use of an immunomodulator medication, and in doing so suggests a possible mechanism speaking to the immune system's role in the etiology of some cases of catatonia.
ISSN:1533-4112
DOI:10.1097/YCT.0000000000000650